希少疾患市場調査

---

希少疾患の市場調査は、関係者が治療のギャップを特定し、患者の治療へのアクセスを改善し、全体的な患者体験を向上させるのに役立ちます。

What Is Rare disease Market research?

希少疾患の市場調査では、市場の動向、治療状況、患者の治療過程など、希少疾患の複雑さを深く掘り下げます。希少疾患のニュアンスを理解することで、関係者は、医薬品開発を加速し、診断能力を向上させ、人生を変えるような治療法への患者のアクセスを強化するためのターゲットを絞った戦略を立てることができます。

この市場調査は、人口のごく一部に影響を及ぼす希少疾患に関連する特有の課題、ニーズ、機会を理解することに重点を置いています。これは、治療法の開発、患者の転帰の改善、希少疾患に関する認識の向上を目指す製薬会社、医療提供者、政策立案者、患者支援団体にとって不可欠です。この情報は、関係者が研究開発の取り組みに優先順位を付け、リソースを効果的に割り当てするのに役立ちます。

Rare Disease Market Research: How Leading Pharma Builds Launch Confidence

Rare disease market research operates under conditions most commercial teams rarely encounter. Patient populations are small, clinicians are scattered, and payer logic differs from mass-market therapeutics. The firms that win in orphan indications treat this scarcity as a structural advantage, not a constraint.

The economics reward it. A single approved therapy in a 5,000-patient indication can generate revenue that rivals a primary care blockbuster, with shorter sales cycles and durable pricing. The intelligence required to get there looks nothing like conventional pharmaceutical research.

Why Rare Disease Market Research Demands a Different Operating Model

Conventional pharma research relies on large physician panels, claims data, and quantitative HCP surveys calibrated to high-prevalence conditions. In orphan indications, that machinery breaks. A neurologist may treat three patients with a given lysosomal storage disorder across an entire career. National claims databases under-code or miscode the disease entirely. Patient advocacy organizations, not health systems, often hold the most accurate prevalence estimates.

The shift this forces on commercial teams is methodological. KOL mapping moves from volume-weighted to network-weighted, identifying the 40 to 80 referring centers that actually diagnose and treat. Patient journey mapping extends backward into the diagnostic odyssey, often seven to ten years from symptom onset. Real-world evidence strategy starts at registry design, not post-launch.

According to SIS International Research, commercial leaders launching orphan therapies consistently underestimate the share of total addressable patients who remain undiagnosed at the point of approval, often by a factor of two to three. The firms that close this gap early build diagnostic-uplift programs into the launch plan rather than treating them as a post-launch sales problem.

Where the Best Launch Teams Concentrate Their Intelligence Spend

Five evidence streams separate strong rare disease launches from average ones. Each requires primary research because secondary sources are thin or absent.

Diagnostic pathway reconstruction. Mapping the actual sequence of specialists, tests, and misdiagnoses a patient encounters before confirmation. This drives screening program design and HCP education targeting.

Treating-center identification. Locating the specific institutions and physicians who manage the bulk of diagnosed patients. In ultra-rare indications, 60 to 80 percent of treated patients concentrate in fewer than 50 centers globally.

Payer value story testing. Pressure-testing the HTA submission evidence against actual reviewers in the United States, Germany, France, the United Kingdom, and Japan before dossier lock. Orphan pricing requires a defensible budget impact model and a credible long-term outcomes argument.

Patient and caregiver burden quantification. Direct evidence of caregiving hours, productivity loss, and out-of-pocket spend. NICE, IQWiG, and HAS increasingly weight these inputs in value assessments.

Competitive pipeline intelligence. Tracking the 8 to 15 assets that may share an indication or mechanism, including academic programs and gene therapies that conventional competitive databases miss.

The Methodologies That Actually Work in Small Populations

Sample sizes that would fail a primary care study deliver decision-grade signal in rare disease when designed correctly. SIS International conducts B2B expert interviews with 25 to 40 specialists per indication across the United States, EU5, and Japan, supplemented by ethnographic research with patient and caregiver dyads. The output supports indication prioritization, launch sequencing, and formulary positioning decisions that move hundreds of millions in NPV.

Patient-side methodology requires equal rigor. SIS International’s structured interviews with commercial leaders at biotech and large pharma indicate that the highest-value patient insights come from longitudinal recruitment through advocacy partnerships rather than one-time panel buys, particularly for indications where misdiagnosis rates exceed 50 percent. The advocacy channel also surfaces sub-segments, such as adult-onset versus pediatric-onset Pompe disease, that aggregate panels collapse into a single cell.

Geographic design matters more than in mass-market work. A study covering only the United States misses the reimbursement dynamics that dominate European launch decisions. SIS International recently scoped a mixed-methodology rare disease engagement in Brazil targeting 200 stakeholders, reflecting the rising importance of Latin American markets in orphan strategy as ANVISA aligns more closely with EMA pathways.

The SIS Rare Disease Intelligence Stack

A four-layer framework organizes the evidence base supporting an orphan launch:

Source: SIS International Research

Each layer feeds the next. Epidemiology sizes the prize. Clinical pathway analysis defines the salesforce footprint. Patient experience drives the value story. Access work confirms the price corridor. Skipping any layer creates blind spots that surface during launch, when correction is expensive.

What Separates Top-Quartile Orphan Launches

The companies extracting the most value from rare disease portfolios share three habits. They start commercial intelligence at Phase 2a, not Phase 3 readout. They treat advocacy organizations as research partners with formal governance, not stakeholders to be managed. And they invest in launch sequencing analysis across multiple indications, recognizing that a gene therapy platform with five potential indications requires a portfolio view that single-asset research cannot provide.

Pricing discipline is the other differentiator. Orphan therapies face increasing scrutiny from ICER in the United States and from joint EU HTA assessments. Companies that pre-test their value story with simulated payer reviewers, including former NICE and IQWiG assessors, enter negotiations with a tighter evidence package and shorter time to reimbursement.

The opportunity in rare disease market research is structural. Roughly 7,000 conditions meet the orphan definition, fewer than 600 have approved therapies, and gene and cell therapy platforms are expanding the addressable list. Commercial teams that build a repeatable intelligence engine, rather than commissioning ad hoc studies per asset, compound their advantage across the pipeline.

Key Questions

How is rare disease market research different from conventional pharmaceutical research? It relies on small-N expert interviews, advocacy partnerships, and registry analysis rather than large physician panels and claims data. Patient populations are too small and under-coded for conventional secondary sources to support launch decisions.

When should commercial teams begin rare disease market research? Phase 2a is the practical starting point. Diagnostic pathway mapping, KOL network identification, and payer value story development each require 12 to 24 months of iterative work before launch.

What sample size is appropriate for rare disease HCP research? 25 to 40 specialists per indication across the United States, EU5, and Japan typically delivers decision-grade signal, provided respondents are network-weighted treating physicians rather than general specialists.

Why are patient advocacy organizations central to rare disease research? They hold the most accurate prevalence estimates, control access to diagnosed patient communities, and surface sub-segments that commercial panels miss. Formal partnerships outperform transactional recruitment.

What is the biggest commercial risk in orphan launches? Underestimating the undiagnosed share of the addressable population. Strong launches build diagnostic-uplift programs into the commercial plan rather than treating diagnosis as a downstream sales problem.

SISインターナショナルについて

SISインターナショナル 定量的、定性的、戦略的な調査を提供します。意思決定のためのデータ、ツール、戦略、レポート、洞察を提供します。また、インタビュー、アンケート、フォーカス グループ、その他の市場調査方法やアプローチも実施します。 お問い合わせ 次の市場調査プロジェクトにご利用ください。